Literature DB >> 25501604

Prognostic factors for pancreatic neuroendocrine neoplasms (pNET) and the risk of small non-functioning pNET.

M Lombardi1, N De Lio2, N Funel3, C Sardella4, D Russo4, C Urbani4, G Rossi5, D Campani3, E Martino4, C Marcocci4, U Boggi2, F Bogazzi4.   

Abstract

BACKGROUND: Non-functioning (NF) pancreatic neuroendocrine tumors (pNET) often have an indolent outcome. A consensus to submit patients with large (>2 cm) NF-pNET to surgery already exists; but a conservative approach for small (≤2 cm) NF neoplasms has been proposed. AIM: To identify prognostic factors for survival and progression free survival (PFS) of NF-pNET, evaluating whether surgery may be avoided for small NF-pNET. SUBJECTS AND METHODS: Retrospective study of 77 consecutive patients with pNET submitted to surgery, of which 60 were NF. Pathological tissues were revised according to the 2000 and 2010 WHO classifications. Risk factors for survival and PFS were evaluated using the Kaplan-Meier method and the Cox regression model.
RESULTS: The 8-year cause-specific survival of NF-pNET was 79.3%. At univariate analysis, high grading, high staging, large tumors, angioinvasion and peri-pancreatic infiltration were significantly associated with a shorter survival; at multivariate analysis only peri-pancreatic infiltration was significantly associated with a shorter NF-pNET survival. Most small NF-pNET were grade 1 (74%), compared to large NF-pNET (27%). Distant metastases were present in 29.7% (n = 11) and 17.4% (n = 4) of patients with large or small NF-pNET, respectively; among the 19 small NF-pNET without metastasis, five had a local malignancy (lymph node metastasis or local infiltration); thus, 39% of the 23 NF-pNET, turned out to have a malignant potential.
CONCLUSIONS: Among NF-pNET, large neoplasms were associated with worse outcomes; however, small NF-pNET do not seem to have an invariable benign behavior. Whether surgery should be avoided in all patients with small NF-pNET is questionable.

Entities:  

Keywords:  Grading; Pancreatic neuroendocrine tumors; Staging; Surgery; Treatment

Mesh:

Year:  2014        PMID: 25501604     DOI: 10.1007/s40618-014-0219-x

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  28 in total

1.  ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary.

Authors:  Marianne Pavel; Eric Baudin; Anne Couvelard; Eric Krenning; Kjell Öberg; Thomas Steinmüller; Martin Anlauf; Bertram Wiedenmann; Ramon Salazar
Journal:  Neuroendocrinology       Date:  2012-02-15       Impact factor: 4.914

2.  The ASA Physical Status Classification: inter-observer consistency. American Society of Anesthesiologists.

Authors:  P H K Mak; R C H Campbell; M G Irwin
Journal:  Anaesth Intensive Care       Date:  2002-10       Impact factor: 1.669

3.  Ki-67 grading of nonfunctioning pancreatic neuroendocrine tumors on histologic samples obtained by EUS-guided fine-needle tissue acquisition: a prospective study.

Authors:  Alberto Larghi; Gabriele Capurso; Antonella Carnuccio; Riccardo Ricci; Sergio Alfieri; Domenico Galasso; Francesca Lugli; Antonio Bianchi; Francesco Panzuto; Laura De Marinis; Massimo Falconi; Gianfranco Delle Fave; Giovanni Battista Doglietto; Guido Costamagna; Guido Rindi
Journal:  Gastrointest Endosc       Date:  2012-09       Impact factor: 9.427

4.  Prognostic factors at diagnosis and value of WHO classification in a mono-institutional series of 180 non-functioning pancreatic endocrine tumours.

Authors:  R Bettini; L Boninsegna; W Mantovani; P Capelli; C Bassi; P Pederzoli; G F Delle Fave; F Panzuto; A Scarpa; M Falconi
Journal:  Ann Oncol       Date:  2008-01-21       Impact factor: 32.976

5.  Pancreatic neuroendocrine tumors: the impact of surgical resection on survival.

Authors:  Joshua S Hill; James T McPhee; Theodore P McDade; Zheng Zhou; Mary E Sullivan; Giles F Whalen; Jennifer F Tseng
Journal:  Cancer       Date:  2009-02-15       Impact factor: 6.860

6.  Lanreotide in metastatic enteropancreatic neuroendocrine tumors.

Authors:  Martyn E Caplin; Marianne Pavel; Jarosław B Ćwikła; Alexandria T Phan; Markus Raderer; Eva Sedláčková; Guillaume Cadiot; Edward M Wolin; Jaume Capdevila; Lucy Wall; Guido Rindi; Alison Langley; Séverine Martinez; Joëlle Blumberg; Philippe Ruszniewski
Journal:  N Engl J Med       Date:  2014-07-17       Impact factor: 91.245

7.  Prognostic score predicting survival after resection of pancreatic neuroendocrine tumors: analysis of 3851 patients.

Authors:  Karl Y Bilimoria; Mark S Talamonti; James S Tomlinson; Andrew K Stewart; David P Winchester; Clifford Y Ko; David J Bentrem
Journal:  Ann Surg       Date:  2008-03       Impact factor: 12.969

Review 8.  The gastroenteropancreatic neuroendocrine cell system and its tumors: the WHO classification.

Authors:  Günter Klöppel; Aurel Perren; Philipp U Heitz
Journal:  Ann N Y Acad Sci       Date:  2004-04       Impact factor: 5.691

9.  Improved histologic and clinicopathologic criteria for prognostic evaluation of pancreatic endocrine tumors.

Authors:  Stefano La Rosa; Catherine Klersy; Silvia Uccella; Linda Dainese; Luca Albarello; Angelica Sonzogni; Claudio Doglioni; Carlo Capella; Enrico Solcia
Journal:  Hum Pathol       Date:  2008-08-20       Impact factor: 3.466

10.  TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system.

Authors:  G Rindi; G Klöppel; H Alhman; M Caplin; A Couvelard; W W de Herder; B Erikssson; A Falchetti; M Falconi; P Komminoth; M Körner; J M Lopes; A-M McNicol; O Nilsson; A Perren; A Scarpa; J-Y Scoazec; B Wiedenmann
Journal:  Virchows Arch       Date:  2006-09-12       Impact factor: 4.064

View more
  10 in total

1.  The North American Neuroendocrine Tumor Society Consensus Paper on the Surgical Management of Pancreatic Neuroendocrine Tumors.

Authors:  James R Howe; Nipun B Merchant; Claudius Conrad; Xavier M Keutgen; Julie Hallet; Jeffrey A Drebin; Rebecca M Minter; Terry C Lairmore; Jennifer F Tseng; Herbert J Zeh; Steven K Libutti; Gagandeep Singh; Jeffrey E Lee; Thomas A Hope; Michelle K Kim; Yusuf Menda; Thorvardur R Halfdanarson; Jennifer A Chan; Rodney F Pommier
Journal:  Pancreas       Date:  2020-01       Impact factor: 3.327

2.  Role of contrast-enhanced ultrasound to define prognosis and predict response to biotherapy in pancreatic neuroendocrine tumors.

Authors:  M Del Prete; A Di Sarno; R Modica; F Lassandro; A Giorgio; A Bianco; M Muto; M Gasperi; F Del Prete; A Colao; V Montesarchio; A Faggiano
Journal:  J Endocrinol Invest       Date:  2017-06-30       Impact factor: 4.256

3.  Robotic enucleations of pancreatic benign or low-grade malignant tumors: preliminary results and comparison with robotic demolitive resections.

Authors:  Ilenia Bartolini; Lapo Bencini; Marco Bernini; Marco Farsi; Massimo Calistri; Mario Annecchiarico; Luca Moraldi; Andrea Coratti
Journal:  Surg Endosc       Date:  2018-11-12       Impact factor: 4.584

Review 4.  Prognostic and predictive factors on overall survival and surgical outcomes in pancreatic neuroendocrine tumors: recent advances and controversies.

Authors:  Lingaku Lee; Tetsuhide Ito; Robert T Jensen
Journal:  Expert Rev Anticancer Ther       Date:  2019-11-27       Impact factor: 4.512

Review 5.  Pancreatic Neuroendocrine Tumors (panNETs): Analysis of Overall Survival of Nonsurgical Management Versus Surgical Resection.

Authors:  Paige Finkelstein; Rishika Sharma; Omar Picado; Rahul Gadde; Heather Stuart; Caroline Ripat; Alan S Livingstone; Danny Sleeman; Nipun Merchant; Danny Yakoub
Journal:  J Gastrointest Surg       Date:  2017-03-02       Impact factor: 3.452

Review 6.  The treatment of hyperinsulinemic hypoglycaemia in adults: an update.

Authors:  M V Davi; A Pia; V Guarnotta; G Pizza; A Colao; A Faggiano
Journal:  J Endocrinol Invest       Date:  2016-09-13       Impact factor: 4.256

7.  Impact of Surgery on Non-Functional Pancreatic Neuroendocrine Tumors ≤2 cm: Analyses With Propensity Score-Based Inverse Probability of Treatment Weighting.

Authors:  Jingyuan Ye; Hongyu Wu; Jinzheng Li; Changan Liu
Journal:  Front Surg       Date:  2022-07-08

8.  A Direct Comparison of Patients With Hereditary and Sporadic Pancreatic Neuroendocrine Tumors: Evaluation of Clinical Course, Prognostic Factors and Genotype-Phenotype Correlations.

Authors:  Przemysław Soczomski; Beata Jurecka-Lubieniecka; Aleksandra Krzywon; Alexander Jorge Cortez; Stanisław Zgliczynski; Natalia Rogozik; Małgorzata Oczko-Wojciechowska; Agnieszka Pawlaczek; Tomasz Bednarczuk; Barbara Jarzab
Journal:  Front Endocrinol (Lausanne)       Date:  2021-05-28       Impact factor: 5.555

9.  Impact and Clinical Predictors of Lymph Node Metastases in Nonfunctional Pancreatic Neuroendocrine Tumors.

Authors:  Yu Jiang; Jia-Bin Jin; Qian Zhan; Xia-Xing Deng; Bai-Yong Shen
Journal:  Chin Med J (Engl)       Date:  2015-12-20       Impact factor: 2.628

Review 10.  Current Management of Pancreatic Neuroendocrine Tumors: From Demolitive Surgery to Observation.

Authors:  Ilenia Bartolini; Lapo Bencini; Matteo Risaliti; Maria Novella Ringressi; Luca Moraldi; Antonio Taddei
Journal:  Gastroenterol Res Pract       Date:  2018-07-22       Impact factor: 2.260

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.